# Study Claims Tirzepatide Effects Greater Weight Loss Among Women Compared to Men ## Key Points: – A recent study suggests that tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist, leads to more significant weight loss in women than in men. – The study involved 208 participants who were given tirzepatide and compared the weight loss results between men and women over 72 weeks. – The researchers found that women experienced an average weight loss of 17.0% compared to 14.6% in men, indicating that tirzepatide may be more effective in promoting weight loss in women. – These findings may have implications for tailoring weight loss treatments based on gender differences and could lead to more personalized approaches in obesity management. ## Hot Take: While the study’s results show promising outcomes for women using tirzepatide for weight loss, it’s essential to consult with healthcare professionals before starting any new treatment. If you’re considering weight loss options, reach out to Mindful Evolution through their website or call/text them for personalized telehealth consultations in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia. Weight Loss Disclaimer: Individual results may vary. It’s advisable to seek professional guidance before embarking on any weight loss journey.